Drug Type Antibody drug conjugate (ADC), Bispecific antibody |
Synonyms JSKN 022, JSKN022 |
Action inhibitors, antagonists |
Mechanism ITGB6 inhibitors(integrin subunit beta 6 inhibitors), ITGB8 inhibitors(integrin subunit beta 8 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 14 Oct 2025 |






